EC Number   |
Application |
Reference |
|---|
    1.13.11.31 | drug development |
cardiac 12/15-LOX is involved in the development of heart failure and inhibition of 12/15-LOX may be a novel treatment for this condition |
704901 |
| 1.13.11.31 | drug development |
induction of pro-carcinogenic 12-LOX pathway by an anticancer ceramide, which may be relevant to cancer biologists studying drug resistant tumors and devising potent anticancer therapeutic strategies to treat drug resistant tumors. Induction of 12-LOX pathway by ceramide may have implications in understanding pathophysiology of neurodegenerative diseases involving reactive oxygen species generation and inflammation |
705902 |
| 1.13.11.31 | drug development |
inhibition of 12/15-LOX provides robust protection against cell death preventing mitochondrial damage in oxidative stress-related brain injury |
705256 |
| 1.13.11.31 | drug development |
p12-LOX pathway may be an effective target of chemoprevention for skin carcinogenesis |
703078 |
| 1.13.11.31 | medicine |
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes |
765145 |
| 1.13.11.31 | medicine |
activity of 12S-lipoxygenase is hardly observed in liver cytosol of normal chow-fed mice but is clearly detectable in that of nonalcoholic steatohepatitis model mice prepared by feeding a methionine and choline-deficient diet |
765022 |
| 1.13.11.31 | medicine |
application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro. Maresin 1 (MaR1) and resolvin D1 (RvD1), 12/15-LOX-derived specialized proresolving mediators (SPMs), inhibited cytokine production of ILC2s at nanomolar concentration |
764729 |
| 1.13.11.31 | medicine |
blood platelet enzyme 12-LOX modulates FcgammaRIIa signaling and presents a viable therapeutic target in the prevention of immune-mediated thrombosis |
742190 |
| 1.13.11.31 | medicine |
humans acutely treated with specific beta3-adrenergic agonist mirabegron display elevated levels of 12-LOX metabolites in the circulation, and significantly higher levels of 12-hydroxyeicosapentaenoic acid and 14-hydroxydocosahexaenoic acid are found in the media of brown adipocytes treated with the beta3-adrenergic agonist CL316,243 for 4 hours |
764439 |
| 1.13.11.31 | medicine |
hypoxia increases the formation of endogenous 12-hydroxyeicosatetraenoic acid through stimulation of 12-lipoxygenase. 12-hydroxyeicosatetraenoic acid promotes endothelial cell migration and tube formation, whereas it inhibits the serum deprivation-induced apoptotic responses under hypoxia. The regulatory effects of 12-lipoxygenase/12-hydroxyeicosatetraenoic acid on pulmonary artery endothelial cells, at least in part, depend on phosphatidylinositol 3-kinase (PI3K)/Akt signaling activatio |
763866 |
